Loading
Life sciences · Journal article
Pharmaceutics · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Neratinib (NTB) is a potent pan-HER inhibitor, but its oral bioavailability is limited due to poor aqueous solubility, low permeability, and gastrointestinal toxicity. This study incorporated a bioactive transdermal system by incorporating NTB-loaded nanovesicles of Ocimum basilicum oil (NTB-OOs) into dissolving microneedles of PVA/PVP–propolis. Methods: Ocimum basilicum oil was characterized by gas chromatography–mass spectrometry (GC–MS). NTB-OOs were screened by I-optimal design and evaluated for vesicular properties, stability, release, skin permeation, and cytotoxicity. The optimized vesicles were loaded in propolis microneedles and evaluated mechanically, ex vivo, and in MCF-7 cells and Ehrlich solid carcinoma-bearing mice. Results: GC–MS revealed a volatile profile rich in linalool, methyl jasmonate, and a cyclopenta[g]-2-benzopyran derivative with reported antioxidant and anticancer activities. The optimized NTB-OOs showed a particle size of (198.9 ± 0.98 nm), entrapment efficiency of (88.9 ± 0.45%), PDI of (0.16 ± 0.01), zeta potential of (−23.1 ± 0.35 mV), and six-month stability. The microneedles provided zero-order release (48–50% after 24 h) and ex vivo permeation (~3500 µg/cm2), which were 2.7- and 1.2-fold higher than those of the NTB suspension and NTB-OOs, respectively. NTB-OOs reduced MCF-7 IC50 from 11.1 to 5.1 µg/mL. In vivo, NTB-OOs/propolis microneedles achieved 75.6% tumor inhibition, increased mean survival from 19 to 26.5 days, and raised the T/C ratio to 139.5%. They also induced apoptosis and downregulated the expression of HER-2, EGFR, VEGF-A, and Bcl-2. Conclusions: The multifunctional nanovesicle–propolis microneedle platform improves NTB solubilization, controlled release, dermal delivery, and antitumor efficacy, supporting its potential for minimally invasive localized breast cancer therapy.